Mazdutide vs Semaglutide
Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Mazdutide
4–4 mg
Semaglutide
0.5–1 mg
Frequency
Mazdutide
Once daily
Semaglutide
Once weekly
Administration
Mazdutide
Subcutaneous injection
Semaglutide
Subcutaneous injection
Cycle length
Mazdutide
Ongoing/indefinite
Semaglutide
Ongoing/indefinite
Onset speed
Mazdutide
Moderate (1-2 weeks)
Semaglutide
Moderate (1-2 weeks)
Evidence level
Mazdutide
Strong human trials (Phase 3 or FDA approved)
Semaglutide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Weight Loss
Blood Sugar Control
Metabolic Health
Appetite Control
Heart Protection
Compound specifications
Mazdutide
Molecular formula
C210H322N46O67
Molecular weight
4563.1 Da
Half-life
Approximately 8 days
Bioavailability
Subcutaneous bioavailability characteristic of acylated peptide analogs
CAS number
2259884-03-0
Semaglutide
Molecular formula
C187H291N45O59
Molecular weight
4113.58 g/mol
Half-life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS number
910463-68-2
Dosing compared
Mazdutide
Subcutaneous
Initial titration weeks
1.5 mg
Once weekly · Initial titration weeks
GLORY-1 Phase 3 starting dose; mazdutide was initiated at 1.5 mg once weekly and titrated stepwise toward the target maintenance dose to limit GI effects [6].
Weeks 32-48
4 mg
Once weekly · Maintenance (32-48 weeks in trial)
GLORY-1 Phase 3 maintenance dose; produced about 11-12% mean body-weight reduction. Approved in China at this strength for weight management [6].
Weeks 32-48
6 mg
Once weekly · Maintenance (32-48 weeks in trial)
GLORY-1 Phase 3 higher maintenance dose; produced about 13-15% mean body-weight reduction. Approved in China at this strength alongside the 4 mg dose [6].
Semaglutide
Subcutaneous
4 weeks
0.25 mg
Once weekly · 4 weeks
This is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
At least 4 weeks at each step
0.5-1 mg
Once weekly · At least 4 weeks at each step
After the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
Ongoing/maintenance
2-2.4 mg
Once weekly · Ongoing/maintenance
The highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.
Oral
30 days
3 mg
Once daily · 30 days
The pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
30+ days
7 mg
Once daily · 30+ days
After the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
Ongoing/maintenance
14 mg
Once daily · Ongoing/maintenance
The highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].
Best suited for
Mazdutide
Individuals seeking substantial weight loss exceeding 15% body weight
Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. [6][7] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adults with type 2 diabetes requiring superior glycemic management
Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. [1][15] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with obesity-related metabolic comorbidities
Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. [6][18] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking dual-mechanism metabolic therapy
Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. [4][5] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Semaglutide
People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].
Side effects
Mazdutide
Common
- Nausea
- Diarrhea
- Decreased Appetite
Uncommon
- Vomiting
- Injection Site Reactions
Serious
- Acute Pancreatitis
- Acute Cholecystitis and Biliary Disease
- Severe Nausea and Gastrointestinal Intolerance
Semaglutide
Common
- Nausea
- Constipation or Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Loss (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
Mazdutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
Mazdutide (Innovent/Lilly GLP-1 and glucagon dual agonist) is approved in China for weight management and type 2 diabetes. [4] Its safety profile is dominated by gastrointestinal side effects, mostly mild to moderate. [7][11] Nausea/vomiting occur in 40-50% of subjects at higher doses; [7][12] weight loss averaging 12-18% observed. [6][7] Pancreatitis risk monitoring required; [9][10] calcitonin was monitored, with no values of 20 ng/L or higher in phase 2. [9] Heart rate increases 5-9 bpm; [9] no serious cardiac safety signals. Developmental program focuses on tolerability optimization.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Known hypersensitivity to mazdutide or any formulation excipients
- History of severe pancreatitis
- Severe renal impairment (eGFR <15 mL/min) without clinical data
Semaglutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [7]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
- History of serious allergic reaction to semaglutide [7]
Which is right for you?
Choose Mazdutide if...
- Individuals seeking substantial weight loss exceeding 15% body weight
- Adults with type 2 diabetes requiring superior glycemic management
- Patients with obesity-related metabolic comorbidities
- Those seeking dual-mechanism metabolic therapy
Choose Semaglutide if...
- Significant weight loss
- Long-term weight management
- Cardiovascular risk reduction
- Blood sugar control